UK's Synthace raises $35M in Series C; Oncology and inflammatory disease biotech Deka hauls in $20M Series A
UK-based AI-assisted R&D biotech Synthace just wrapped up a Series C round, bringing in $35 million.
Per a company statement this morning, the investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to expand across the Atlantic into the US. This includes plans to expand its leadership team by bringing in new VPs of marketing and sales to join US-based Guy Levy-Yurista, Synthace’s CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.